281 related articles for article (PubMed ID: 32820953)
1. The potential of PSMA-targeted alpha therapy in the management of prostate cancer.
Filippi L; Chiaravalloti A; Schillaci O; Bagni O
Expert Rev Anticancer Ther; 2020 Oct; 20(10):823-829. PubMed ID: 32820953
[TBL] [Abstract][Full Text] [Related]
2. First Clinical Results for PSMA-Targeted α-Therapy Using
Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals.
Ndlovu H; Mokoala KMG; Lawal I; Emmett L; Sathekge MM
PET Clin; 2024 Jul; 19(3):371-388. PubMed ID: 38658230
[TBL] [Abstract][Full Text] [Related]
5. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
[TBL] [Abstract][Full Text] [Related]
6. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Miyahira AK; Pienta KJ; Morris MJ; Bander NH; Baum RP; Fendler WP; Goeckeler W; Gorin MA; Hennekes H; Pomper MG; Sartor O; Tagawa ST; Williams S; Soule HR
Prostate; 2018 Aug; 78(11):775-789. PubMed ID: 29717499
[TBL] [Abstract][Full Text] [Related]
7. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
Haberkorn U; Eder M; Kopka K; Babich JW; Eisenhut M
Clin Cancer Res; 2016 Jan; 22(1):9-15. PubMed ID: 26728408
[TBL] [Abstract][Full Text] [Related]
8. Radium 223 dichloride for prostate cancer treatment.
Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.
Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen Å
Clin Cancer Res; 2024 Jun; 30(11):2531-2544. PubMed ID: 38593212
[TBL] [Abstract][Full Text] [Related]
10. PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.
Ahmadzadehfar H; Rahbar K; Essler M; Biersack HJ
Semin Nucl Med; 2020 Jan; 50(1):98-109. PubMed ID: 31843065
[TBL] [Abstract][Full Text] [Related]
11. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
Vogelzang NJ
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
[TBL] [Abstract][Full Text] [Related]
13. Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
15. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
16. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
17. Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.
Kratochwil C; Giesel FL; Heussel CP; Kazdal D; Endris V; Nientiedt C; Bruchertseifer F; Kippenberger M; Rathke H; Leichsenring J; Hohenfellner M; Morgenstern A; Haberkorn U; Duensing S; Stenzinger A
J Nucl Med; 2020 May; 61(5):683-688. PubMed ID: 31601699
[TBL] [Abstract][Full Text] [Related]
18. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
19.
Ballal S; Yadav MP; Sahoo RK; Tripathi M; Dwivedi SN; Bal C
Prostate; 2021 Jun; 81(9):580-591. PubMed ID: 33905559
[TBL] [Abstract][Full Text] [Related]
20. Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.
Awang ZH; Essler M; Ahmadzadehfar H
Radiat Oncol; 2018 May; 13(1):98. PubMed ID: 29792198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]